Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02870231 | Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With Obesity | PHASE1 | COMPLETED | 187 | — | — | Aug 18, 2016 | Sep 3, 2017 | Sep 5, 2018 | 2 | United States |
| NCT02835235 | A Trial Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Male and Female Subjects Being Overweight or With Obesity | PHASE1 | COMPLETED | 48 | — | — | Jul 26, 2016 | Jul 7, 2017 | Jan 8, 2018 | 2 | United States |
| NCT02235961 | Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects | PHASE1 | COMPLETED | 163 | — | — | Sep 4, 2014 | Jul 6, 2016 | Jul 27, 2017 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| NNC9204-0530 / Placebo and Liraglutide 1.8 | EXPERIMENTAL | - |
| NNC9204-0530 /Placebo and Liraglutide 3.0 | ACTIVE_COMPARATOR | - |
| NNC9204-0530 | EXPERIMENTAL | Dose-escalation within the cohort before reaching final dose |
| Placebo | PLACEBO_COMPARATOR | - |
| Part 1 | EXPERIMENTAL | - |
| Part 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| NNC9204-0530 | DRUG | Once-daily subcutaneous (s.c., under the skin) administration. |
| liraglutide | DRUG | Once-daily subcutaneous (s.c., under the skin) administration. |
| placebo | DRUG | Once-daily subcutaneous (s.c., under the skin) administration |
Inclusion Criteria: * Body mass index between 25.0 and 39.9 kg/m\^2 (both inclusive) at screening. * Male or female, age between 18 and 55 years (both inclusive) at the time of signing informed consent Exclusion Criteria: * Any clinically significant weight change (equal or above 5% self-reported...